Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
BMC Vet Res ; 16(1): 275, 2020 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-32762697

RESUMEN

BACKGROUND: Feline panleukopenia virus (FPV) is an etiologic pathogen of feline panleukopenia that infects all members of Felidae including tigers (Panthera tigris). Vaccinations against FPV among wild felid species have long been practiced in zoos worldwide. However, few studies have assessed the tiger immune response post-vaccination due to the absence of a serological diagnostic tool. To address these limitations, this study aimed to develop an in-house indirect enzyme-linked immunosorbent assay (ELISA) for the monitoring of tiger antibody levels against the feline panleukopenia vaccine by employing the synthesized subunit capsid protein VP2. An in-house horseradish peroxidase (HRP) conjugated rabbit anti-tiger immunoglobulin G (IgG) polyclonal antibody (HRP-anti-tiger IgG) was produced in this study and employed in the assay. It was then compared to a commercial HRP-conjugated goat anti-cat IgG (HRP-anti-cat IgG). Sensitivity and specificity were evaluated using the Bayesian model with preferential conditional dependence between HRP-conjugated antibody-based ELISAs and hemagglutination-inhibition (HI) tests. RESULTS: The posterior estimates for sensitivity and specificity of two indirect ELISA HRP-conjugated antibodies were higher than those of the HI test. The sensitivity and specificity of the indirect ELISA for HRP-anti-tiger IgG and HRP-anti-cat IgG were 86.5, 57.2 and 86.7%, 64.6%, respectively, while the results of the HI test were 79.1 and 54.1%. In applications, 89.6% (198/221) and 89.1% (197/221) of the tiger serum samples were determined to be seropositive by indirect ELISA testing against HRP-anti-tiger and HRP-anti-cat, respectively. CONCLUSION: To the best of our knowledge, the specific serology assays for the detection of the tiger IgG antibody have not yet been established. The HRP-anti-tiger IgG has been produced for the purpose of developing the specific immunoassays for tigers. Remarkably, an in-house indirect ELISA based on VP2 subunit antigen has been successfully developed in this study, providing a potentially valuable serological tool for the effective detection of tiger antibodies.


Asunto(s)
Ensayo de Inmunoadsorción Enzimática/veterinaria , Tigres/inmunología , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Gatos , Ensayo de Inmunoadsorción Enzimática/métodos , Panleucopenia Felina , Virus de la Panleucopenia Felina/inmunología , Pruebas de Inhibición de Hemaglutinación/veterinaria , Inmunoglobulina G , Sensibilidad y Especificidad , Pruebas Serológicas/veterinaria , Tigres/virología
2.
Vet Sci ; 11(6)2024 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-38922001

RESUMEN

The objective of this study was to investigate the therapeutic effects of inactivated Propionibacterium acnes and lipopolysaccharide derived from Escherichia coli cells in cats affected by feline panleukopenia virus (FPV). A retrospective study of 80 FPV-positive cats was divided into two groups: a treatment group receiving inactivated Propionibacterium acnes and lipopolysaccharide derived from Escherichia coli cells along with supportive treatment and a no-treatment group receiving only supportive treatment. There was no significant difference in the total white blood cell counts between the two groups. However, the total white blood cell counts of both groups were low on day 0 and increased significantly on days 3 and 6 of treatment. Additionally, the white blood cell counts in the treatment group significantly increased during days 3 to 6 compared with those of the no-treatment group (p < 0.01). The mortality rate was not significantly different between the two groups. In a prospective study, the serum and fecal immunoglobulin A (IgA) levels were measured in both groups. There were no significant differences in IgA levels between the two groups in either the serum or feces.

3.
PeerJ ; 12: e17077, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38500523

RESUMEN

Background: Metastatic disease resulting from mammary gland tumors (MGTs) is a known cause of death among dogs and cats. Keys to successful prevention and management strategies involve the accurate recording of diagnostic data. Methods: This retrospective study reviewed the epidemiology and classification of canine mammary gland tumors (CMTs) and feline mammary gland tumors (FMTs), as well as the factors including sex, age, and breed related to the occurrence of these tumors. Accordingly, 1,736 tumor biopsy cases were reported from 2012 to 2019 at Chiang Mai University Small Animal Hospital, Thailand, with 1,639 canine tumor biopsy cases and 97 feline tumor biopsy cases. Results: The proportion of CMTs was reported at 24.5% (401/1,639) for all canine tumor biopsy cases. Benign and malignant tumors were reported at 14.5% (58/401) and 85.5% (343/401) for all CMT cases, respectively. The mean age of dogs affected by benign CMTs was 9.0 ± 3.0 years, which was significantly lower than for malignant CMTs at 9.9 ± 2.8 years (P = 0.0239). According to histopathological classification, benign mixed tumors and simple carcinoma types were highest among benign and malignant CMT cases, respectively. Moreover, female dogs were at significantly higher risk of developing mammary gland tumors (OR = 45.8, 95% CI [3.9-86.0], P < 0.0001) than male dogs, as well as older dogs (>8 years) (OR = 1.7, 95% CI [1.2-2.2], P = 0.0001) compared to young ones (≤8 years). The proportion of FMTs was 37.1% (36/97) for all feline tumor biopsy cases. Benign and malignant tumors for all FMTs were reported at 16.7% (6/36) and 83.3% (30/36), respectively. According to histopathological classifications, adenoma and simple carcinoma were present in the highest proportion among benign and malignant FMTs, respectively. Female cats were at a significantly higher risk of developing mammary gland tumors than male cats (OR = 25.7, 95% CI [3.9-272.8], P < 0.0001). Conclusions and clinical importance: There was a high proportion of MGT cases compared with other tumor cases reported in a secondary care hospital in Chiang Mai, Thailand from 2012 to 2019, and malignant tumor biopsies have been more frequently observed than benign tumor biopsies in both CMT and FMT cases. The resulting data originating from this study can be an aid for veterinary oncologists in better educating clients and planning treatment and prevention strategies and it can be used as a basis for further experimental studies in the oncology section.


Asunto(s)
Carcinoma , Enfermedades de los Gatos , Enfermedades de los Perros , Glándulas Mamarias Humanas , Neoplasias Mamarias Animales , Neoplasias de las Glándulas Sudoríparas , Humanos , Gatos , Perros , Animales , Masculino , Femenino , Niño , Enfermedades de los Gatos/epidemiología , Tailandia/epidemiología , Estudios Retrospectivos , Glándulas Mamarias Humanas/patología , Atención Secundaria de Salud , Enfermedades de los Perros/diagnóstico , Carcinoma/patología , Biopsia/veterinaria , Neoplasias Mamarias Animales/epidemiología , Hospitales
4.
Vet Sci ; 9(1)2022 Jan 09.
Artículo en Inglés | MEDLINE | ID: mdl-35051105

RESUMEN

Dermatophytosis is a disease caused by dermatophytes, a group of fungi that can cause disease both in humans and animals. The important genera that are pathogenic in animals include Trichophyton and Microsporum. Microsporum canis is an important species because it can cause zoonosis and is commonly found in domestic animals. Cats, which live very close to humans, may expose humans to this pathogen. This research focused on the epidemiology of M. canis found in cats. Hair samples were collected via the Mackenzie technique from cats with and without skin lesions, preliminarily examined with 10% KOH preparation, and cultured for fungal identification. Samples were confirmed with molecular techniques including polymerase chain reaction, gel electrophoresis, and sequencing. Samples were collected from 138 cats located in 93 households, 43 from cats with skin lesions (31.16%) and 95 from cats without skin lesions (68.84%). Eighteen cats with lesions (13.04%) and ten cats without lesions (7.2%) were found to carry M. canis. In eleven of the eighteen cats both with skin lesions and positive for M. canis (61.11%), the pathogen was found both at the site of the lesion and at other sites in the body. Because the pathogen can be found in the hair of cats with and without skin lesions, owners, keepers, veterinarians, and others who come into contact with these animals are at risk of infection if they are not aware or do not take precautions after contact with them.

5.
J Pharmacol Sci ; 112(2): 242-6, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20093793

RESUMEN

Overexpression of heat shock protein 70 kDa (HSP70) is known to confer cellular protection against ischemia-reperfusion (I/R) injury. Radicicol, a HSP90 inhibitor, has been reported to induce the expression of HSP70 protein. Here we studied whether radicicol attenuated renal I/R injury in vivo. Treatment of mice with radicicol ameliorated renal I/R injury and increased renal HSP70 mRNA and protein. Administration of radicicol with quercetin, an inhibitor of HSP70 induction, eliminated the renoprotective effect of radicicol. Our results suggest that the up-regulation of renal HSP70 protein by radicicol leads to a novel drug therapy against renal I/R injury.


Asunto(s)
Riñón/efectos de los fármacos , Macrólidos/farmacología , Daño por Reperfusión/prevención & control , Animales , Proteínas HSP70 de Choque Térmico/efectos de los fármacos , Proteínas HSP70 de Choque Térmico/genética , Proteínas HSP70 de Choque Térmico/metabolismo , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Riñón/patología , Masculino , Ratones , Quercetina/farmacología , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Regulación hacia Arriba/efectos de los fármacos
6.
Vet Sci ; 7(3)2020 Aug 10.
Artículo en Inglés | MEDLINE | ID: mdl-32784970

RESUMEN

Melanoma-associated antigen-A (MAGE-A), a family of cancer/testis antigens, has been recognized as a potential target molecule for cancer immunotherapy. However, there has been very little information available with regard to this antigen in dogs. This study aimed to investigate the expression of MAGE-A in canine mammary gland tumors (CMTs) using immunohistochemistry and immunoblotting with human monoclonal MAGE-A antibody 6C1. The present study has provided evidence of cross-reactivity of the canine MAGE-A expression with the human MAGE-A antibody in CMTs. The MAGE-A antigens were expressed in moderate- and high-grade malignant CMTs (22.22%, 2/9), but no expression was observed in benign CMTs. The immunohistochemical staining of canine MAGE antigen in CMT cells showed nuclear and nuclear-cytoplasmic expression patterns that may be involved with the mitotic cell division of tumor cells. Molecular weights of the canine MAGE-A antigen presented in this study were approximately 42-62 kDa, which were close to those of other previous studies involving humans and dogs. The findings on this protein in CMTs could supply valuable oncological knowledge for the development of novel diagnostic, prognostic and immunotherapeutic tumor markers in veterinary medicine.

7.
Vet Comp Oncol ; 18(4): 787-795, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32421920

RESUMEN

Canine mammary tumours (CMTs) are regarded as invasive with a high rate of recurrent and metastasis in intact female dogs. Tumour diagnosis, therefore, is an important step in predicting and monitoring tumour progression. This study was designed to identify protein expression on CMTs by employing a proteomic approach. The primary cell culture from benign mixed tumour, simple carcinoma, complex carcinoma and normal mammary gland were established, and two-dimensional electrophoresis (2DE) was subsequently performed. The different spots on each sample type were collected for identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The results indicated that cytokeratin 5 (CK5) and transketolase (TKT) were identified in benign mixed tumour cells and complex carcinoma cells. In contrast, cytokeratin 18 (CK18) and pyruvate kinase PKM were identified in simple carcinoma cells. Moreover, alpha-2-HS-glycoprotein tumour antigen was identified specifically in complex carcinoma cells. In addition, ATP-dependent 6-phosphofructokinase platelet type and elongation factor 2 proteins were observed in benign cells. In conclusion, all expressed proteins in this study have been recognized for acting as their expression that differs from healthy mammary epithelial cells. Expectantly, this study identified the expressed proteins that might be useful in further diagnostic biomarker studies on CMTs.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Enfermedades de los Perros/metabolismo , Neoplasias Mamarias Animales/metabolismo , Proteínas/análisis , Animales , Línea Celular Tumoral , Enfermedades de los Perros/patología , Perros , Electroforesis , Células Epiteliales/metabolismo , Femenino , Neoplasias Mamarias Animales/patología , Espectrometría de Masas , Proteómica , Tailandia
8.
Eur J Pharmacol ; 592(1-3): 138-45, 2008 Sep 11.
Artículo en Inglés | MEDLINE | ID: mdl-18644364

RESUMEN

Although renal ischemia-reperfusion is known to activate the unfolded protein response, the renal site and role of activation of this response following the insult in vivo remains largely unknown. Here we studied the renal spatio-temporal expression pattern of glucose-regulated protein (GRP) 78, a central regulator of the unfolded protein response network, following renal ischemia-reperfusion and the effects of the specific chemical unfolded protein response inducers, tunicamycin and thapsigargin, on renal ischemia-reperfusion injury in mice. Renal ischemia-reperfusion resulted in expression of the spliced form of the X-box binding protein-1 (XBP-1s) transcript, an unfolded protein response target, at 1 and 2 h after the insult. This response was followed by an increase in the GRP78 transcript and protein. The increased amount of GRP78 protein after ischemia-reperfusion was largely localized in proximal tubule cells. Pretreatment with tunicamycin or thapsigargin significantly ameliorated renal dysfunction and injury after ischemia-reperfusion. Taken together with these results, the unfolded protein response was activated following renal ischemia-reperfusion at sites that are susceptible to ischemia-reperfusion injury, and this activation had a protective effect against renal ischemia-reperfusion injury in vivo. Molecules involved in the unfolded protein response may offer new opportunities for pharmacological intervention against renal ischemia-reperfusion injury, which is an important cause of acute kidney injury.


Asunto(s)
Enfermedades Renales/patología , Riñón/patología , Daño por Reperfusión/patología , Animales , Western Blotting , Proteínas de Unión al ADN/biosíntesis , Proteínas de Unión al ADN/genética , Chaperón BiP del Retículo Endoplásmico , Inhibidores Enzimáticos/farmacología , Proteínas de Choque Térmico/biosíntesis , Proteínas de Choque Térmico/genética , Enfermedades Renales/tratamiento farmacológico , Pruebas de Función Renal , Masculino , Ratones , Chaperonas Moleculares/biosíntesis , Chaperonas Moleculares/genética , Pliegue de Proteína , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Factores de Transcripción del Factor Regulador X , Circulación Renal/fisiología , Daño por Reperfusión/tratamiento farmacológico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Tapsigargina/farmacología , Factores de Transcripción/biosíntesis , Factores de Transcripción/genética , Tunicamicina/farmacología , Proteína 1 de Unión a la X-Box
9.
Drug Discov Today ; 11(7-8): 364-70, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16580979

RESUMEN

Acute renal failure (ARF) is a common cause of mortality and morbidity in hospitalized patients. Ischemia is an important cause of ARF, and ARF caused by ischemic injury is referred to as ischemic acute tubular necrosis (ATN). There is growing evidence from models that ischemic ATN is associated with intrarenal inflammation. Consequently, intrarenal inflammation is an attractive target for the development of novel drug therapies for ARF. This review outlines ischemic ATN models, the pathophysiological roles of inflammatory cells such as T and B cells in ischemic ATN models, and effective T and B cell therapeutic reagents.


Asunto(s)
Antiinflamatorios/uso terapéutico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Inflamación/tratamiento farmacológico , Isquemia/tratamiento farmacológico , Necrosis Tubular Aguda/tratamiento farmacológico , Animales , Antiinflamatorios/farmacología , Linfocitos B/efectos de los fármacos , Linfocitos B/metabolismo , Células Cultivadas , Evaluación Preclínica de Medicamentos/métodos , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Inflamación/metabolismo , Isquemia/genética , Isquemia/metabolismo , Riñón/irrigación sanguínea , Necrosis Tubular Aguda/genética , Necrosis Tubular Aguda/metabolismo , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/farmacología , Ácido Micofenólico/uso terapéutico , Análisis de Secuencia por Matrices de Oligonucleótidos , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo
10.
J Pharmacol Sci ; 109(2): 311-4, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19179808

RESUMEN

Activation of the unfolded protein response (UPR) has been suggested to attenuate renal ischemia-reperfusion (I/R) injury. We recently found a compound, namely BIX, that activated the UPR selectively through the activating transcription factor 6 pathway. This study examined the effect of BIX on renal I/R injury in mice. BIX selectively up-regulated renal BiP mRNA and protein. Pretreatment with BIX significantly ameliorated renal I/R injury. Co-administration of BIX and tunicamycin, a non-selective UPR inducer, provided no additional protection. Our results suggest that the UPR activation by BIX leads to a novel drug therapy against renal I/R injury.


Asunto(s)
Isquemia/tratamiento farmacológico , Daño por Reperfusión/prevención & control , Tiocianatos/uso terapéutico , Animales , Chaperón BiP del Retículo Endoplásmico , Proteínas de Choque Térmico/genética , Proteínas de Choque Térmico/metabolismo , Riñón/lesiones , Masculino , Ratones , Ratones Endogámicos , Chaperonas Moleculares/genética , Chaperonas Moleculares/metabolismo , ARN Mensajero/metabolismo , Activación Transcripcional , Tunicamicina/administración & dosificación , Tunicamicina/farmacología , Regulación hacia Arriba
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA